Filing Flows › Tarsus Pharmaceuticals (TARS) › Guidance & outlook

Tarsus Pharmaceuticals (TARS) guidance and outlook

Tarsus Pharmaceuticals' 10-Q filed Nov 3, 2026 makes 23 forward-looking statements.

Guidance and outlook

Forward-looking statements, 10-Q filed Nov 3, 2026

• • the expected potential benefits of strategic collaborations with third parties (including, for example, the receipt of payments, achievement and timing of milestones under license agreements, and the ability of our third party
• We intend to further advance our pipeline with, e.g., lotilaner API to address several diseases in human medicine, including eye care, and infectious disease prevention.
• We are investigating the development of our lotilaner-based product candidates to address targeted diseases with high unmet medical needs, which currently include TP-04, an investigational sterile aqueous gel formulation of lotilaner for the potential treatment of ocular rosacea, and TP-05, an investigational oral tablet formulation of lotilaner for potential Lyme disease prophylaxis and community malaria reduction.
• Enrollment was completed in June 2026 and topline results are expected in the first half of 2027, which we believe could support a Phase 3-ready package by the end of 2027.
• Based on data from a Phase 2b/3 trial and in alignment with feedback from the FDA, we plan to initiate a Phase 3 trial (the “Comfort Trial”) of IRX-101, an investigational ocular antiseptic designed to evaluate the tolerability and safety of IRX-101 compared to povidone-iodine.
• We plan to initiate the Comfort Trial in the first half of 2027, with topline results expected in 2028.
• In connection with the Alkeus Acquisition we acquired ALK-001, an investigational once-daily oral medicine with a differentiated approach designed to reduce toxic Vitamin A dimer formation in the retina, targeting the underlying biology of Stargardt disease.
• In December 2025, we initiated the Kore Trial, evaluating TP-04 for the potential treatment of ocular rosacea, with topline results expected in the first half of 2027.
• We believe TP-05 is currently the only on-demand, oral tablet in development that targets ticks, and potentially prevents Lyme disease transmission.
• Based on this data and in alignment with feedback from the FDA, we plan to initiate the Phase 3 Comfort Trial.
• We are exploring the potential of ALK-001 as an investigational once-daily oral medicine with a differentiated approach designed to reduce toxic Vitamin A dimer formation in the retina, targeting the underlying biology of Stargardt disease, which can lead to blindness.
• The Alkeus Acquisition added a Phase 3 clinical program (the “Northstar Trial”) which is expected to further expand our presence in retina, one of the largest and fastest-growing specialties and is an important advancement in our strategy to become a leading eye care company.

Tarsus Pharmaceuticals' latest quarter

Questions

What does Tarsus Pharmaceuticals expect?

• the expected potential benefits of strategic collaborations with third parties (including, for example, the receipt of payments, achievement and timing of milestones under license agreements, and the ability of our third party We intend to further advance our pipeline with, e.g., lotilaner API to address several diseases in human medicine, including eye care, and infectious disease prevention. We are investigating the development of our lotilaner-based product candidates to address targeted diseases with high unmet medical needs, which currently include TP-04, an investigational sterile aque

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.